Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987375 · ClinicalTrials.gov registry record · Phase 1
Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
A Phase 1 study, sponsored by Eben Rosenthal.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01987375 is a Phase 1 study that was terminated before completion, run by Eben Rosenthal. The registered enrollment target is 1 participants.
The verdict
NCT01987375, a Phase 1 study, was terminated before completion, sponsored by Eben Rosenthal.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is an open label, single institution, Phase 1 dose-escalation study to determine the safety profile of cetuximab-IRDye800 used in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent. Participants will be given a dose of an approved head and neck cancer drug (Cetuximab) along with an investigational study drug called Cetuximab-IRDye800. Cetuximab-IRDye800 is a drug that is given prior to surgery that attaches to cancer cells and appears to make them visible to the doctor when he uses a special camera during the operation. The investigators are evaluating whether or not the use of the study drug along with the special camera will better identify the cancer while patients are in the operating room.
Interventions
- DRUG Cetuximab-IRDye800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01987375
The ClinicalTrials.gov registry entry for NCT01987375 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eben Rosenthal, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetuximab-IRDye800 is the first listed.
NCT01987375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01987375 about?
NCT01987375 is a clinical study titled "Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures". This study is an open label, single institution, Phase 1 dose-escalation study to determine the safety profile of cetuximab-IRDye800 used in subjects with head and neck squamous cell carcinoma (HNSCC) that undergo surgery with curative intent. Participants will be given a dose of an approved head an...
What is the current status of trial NCT01987375?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2015-11. Estimated completion is 2017-04-19.
What interventions are being tested in trial NCT01987375?
The interventions under investigation include: Cetuximab-IRDye800 (DRUG).
Who is sponsoring clinical trial NCT01987375?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.